About: Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies
Creator	Ariza-Heredia, Ella Kmeid, Joumana Sheshadri, Ajay Azzi, Jacques Vakil, Erik Zhu, Yayuan Faiz, Saadia Liang, \| Shah, P Amulya Balagani, \| Chemaly, F Dimpy, \| Lara Bashoura, \| Roy, \|
source	Medline; PMC
abstract	BACKGROUND: Respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) is associated with high mortality in patients with hematologic malignancies (HM). We sought to determine whether allogeneic hematopoietic cell transplant (allo-HCT) recipients would be at higher risk for 60-day mortality. METHODS: We examined a retrospective cohort of adults with HM with or without HCT treated for RSV LRTI (n=154) at our institution from 1996–2013. We defined possible RSV LRTI as RSV detected only in the upper respiratory tract with new radiologic infiltrates and proven RSV LRTI as RSV detected in BAL fluid with new radiologic infiltrates. Immunodeficiency Scoring Index (ISI) and Severe Immunodeficiency (SID) criteria were calculated for HCT recipients. Multivariable logistic regression analyses were performed to identify independent risk factors associated with 60-day all-cause mortality. RESULTS: Mortality was high in HM patients (25%), but there was no difference between those without HCT, autologous or allo-HCT recipients in logistic regression models. Separate multivariate models showed that at RSV diagnosis, neutropenia (OR 8.3, 95% CI 2.8–24.2, p=0.005) and lymphopenia (OR 3.7, 95% CI 1.7–8.2, p=0.001) were associated with 60-day mortality. Proven LRTI was associated with higher 60-day mortality (neutropenia model: OR 4.7, 95% CI 1.7–13.5; lymphopenia model: OR 3.3, 95%CI 1.2–8.8), and higher ICU admission. In HCT recipients, high ISI and very severe immunodeficiency by SID criteria were associated with higher 60-day all-cause mortality. CONCLUSIONS: Mortality is similarly high among HM patients without HCT and HCT recipients. High-grade immunodeficiency and detection of RSV from BAL fluid are associated with higher 60-day mortality.
has issue date	2018-09-21(xsd:dateTime)
bibo:doi	10.1111/tid.12994
bibo:pmid	30195271
has license	green-oa
sha1sum (hex)	262f4ec7b65be8279dc5b6eb4d160647ed42f574
schema:url	https://doi.org/10.1111/tid.12994
resource representing a document's title	Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies
has PubMed Central identifier	PMC6329612
has PubMed identifier	30195271
schema:publication	Transplant Infectious Disease
resource representing a document's body	covid:262f4ec7b65be8279dc5b6eb4d160647ed42f574#body_text
is schema:about of	named entity 'mortality' named entity 'Risk factors' named entity 'corticosteroid' named entity 'LRTI' named entity 'RSV' named entity 'ribavirin' named entity 'immunodeficiency' named entity 'Infection' named entity 'neutropenia' named entity 'World Medical Association' named entity 'neutropenia' named entity 'URTI' named entity 'RSV' named entity 'risk stratification' named entity 'LRTI' named entity 'clinical trials' named entity 'immunodeficiency' named entity 'lower respiratory tract' named entity 'etiology' named entity 'RSV' named entity 'LRTI' named entity 'immunodeficiency' named entity 'LRTI' named entity 'immunofluorescent' named entity 'ribavirin' named entity 'URTI' named entity 'hematopoietic cell' named entity 'infection' named entity 'parainfluenza' named entity 'ISI' named entity 'retrospective cohort' named entity 'RSV' named entity 'multiple myeloma' named entity 'pathogens' named entity 'RSV' named entity 'immunodeficiency' named entity 'RSV' named entity 'backward elimination' named entity 'ribavirin' named entity 'bronchoscopy' named entity 'pulmonologist' named entity 'ISI' named entity 'lower respiratory' named entity 'LRTI' named entity '10.6' named entity 'volume overload' named entity 'multiple myeloma' named entity 'RSV' named entity 'sample size' named entity 'LRTI' named entity 'high-risk' named entity 'upper respiratory tract' named entity 'bronchoscopy' named entity 'Kaplan-Meier curves' named entity 'leukocyte count' named entity 'RSV' named entity 'immunodeficiency' named entity 'The University of Texas MD Anderson Cancer Center' named entity 'immunodeficiency' named entity 'LRTI' named entity 'RSV' named entity 'neutropenia' named entity 'interquartile range' named entity 'Lymphopenia' named entity 'LRTI' named entity 'RSV' named entity 'ISI' named entity 'ISI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software